mimedx group inc (MDXG:NASDAQ CM)
mimedx group inc (MDXG) Snapshot
|
Open
$7.20
|
Previous Close
$7.15
|
|
|
Day High
$7.20
|
Day Low
$6.84
|
|
|
52 Week High
05/17/13 - $7.50
|
52 Week Low
06/7/12 - $1.33
|
|
|
Market Cap
667.8M
|
Average Volume 10 Days
544.4K
|
|
|
EPS TTM
$-0.10
|
Shares Outstanding
95.9M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
mimedx group inc (MDXG) Related Businessweek News
No Related Businessweek News Foundmimedx group inc (MDXG) Details
MiMedx Group, Inc., together with its subsidiaries, operates as an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes. Its biomaterial platform technologies include HydroFix and CollaFix device technologies; and AmnioFix and EpiFix tissue technologies. Its tissue technologies, processed from the human amniotic membrane, utilize its proprietary Purion process to produce minimally manipulated implants. The company supplies amniotic tissues to distributors and original equipment manufacturers for application in the surgical, ophthalmic, orthopedics, spine, wound care, and dental sectors of healthcare. MiMedx Group sells its products directly, as well as through a network of third party sales agents and stocking distributors in the United States and internationally. The company is headquartered in Kennesaw, Georgia.
Last Reported Date: 03/15/13
mimedx group inc (MDXG) Top Compensated Officers
mimedx group inc (MDXG) Key Developments
MiMedx Group, Inc. announced that it has secured a revolving line of credit with Bank of America. The revolving line of credit facility, which is secured by the company's accounts receivable and inventory, allows MiMedx to borrow up to $3.0 million through May 1, 2014. The facility will be used for general corporate purposes.
MiMedx Group, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported net sales of USD 11,556,493 compared to USD 3,705,808 a year ago. Operating loss was USD 226,890 compared to USD 631,365 a year ago. Loss before income tax provision was USD 1,570,133 compared to USD 1,093,652 a year ago. Net loss was USD 1,620,408 compared to USD 1,093,652 a year ago. Basic and diluted net loss per common share was USD 0.02 compared to USD 0.01 a year ago. Adjusted EBITDA was USD 1,119,249 compared to USD 313,985 a year ago. The company reaffirmed its previously communicated goals for second quarter of 2013 revenue to be in the range of USD 11.5 million to USD 13.5 million For the full year 2013 revenue to be in the range of USD 50 million to USD 60 million.
MiMedx Group, Inc. will be added to NASDAQ Composite Index.
| Recently Viewed | |||
| MDXG:US | $6.96 USD | -0.19 |  |
| Company | Last | Change |
| 3M Co | $110.27 USD | -0.14 |
| Integra LifeSciences Holdings Corp | $36.40 USD | -0.11 |
| Shire PLC | 2,168 GBp | +34.00 |
| Stryker Corp | $66.99 USD | -0.25 |
| View Industry Companies | ||
Industry Analysis
MDXG
Industry Average
| Valuation | MDXG | Industry Range |
| Price/Earnings | -- | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | -- | Not Meaningful |
| Price/Cash Flow | -- | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact MIMEDX GROUP INC, please visit www.mimedx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
